Navigation Links
Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
Date:1/22/2008

al insights into the potential utility of RIT in intermediate grade NHL, a subtype where CRs are infrequent with rituximab therapy," noted Jack W. Singer, M.D., Chief Medical Officer of CTI.

The study results are reported in the current issue of CANCER at http://www3.interscience.wiley.com/journal/104532863/issue

Study Details

Between February 2005 and June 2006 26 eligible patients with previously untreated, indolent, nonfollicular NHL (10 marginal zone, 8 lymphocytoplasmic, and 8 small lymphocytic) were treated using a novel regimen that consisted of 6 cycles of fludarabine/mitoxantrone (FM) chemotherapy followed 6 to 10 weeks later by yttrium-90(90Y) ibritumomab tiuxetan (Zevalin(R)). After chemotherapy the overall response rate was 80.5% and included 50% CR and 30.5% PR. Of the 20 patients (13CR/7PR) who were evaluable (at least a PR with normal platelet counts and bone marrow infiltration <25%) for subsequent Zevalin, 100% obtained a CR at the end of treatment. With a median follow up of 20 months, the estimated three-year progression free survival (PFS) was 89.5 percent. The FM treatment was well-tolerated; there were no treatment-related deaths. Reversible hematologic toxicities included neutropenia grade 4 in 5 patients and grade 3 in 13 patients. Only 1 patient developed febrile neutropenia. Following Zevalin administration grade 3-4 thrombocytopenia occurred in 16 of 20 patients with grade 3-4 neutropenia reported in 11 of 20 patients. Four patients received GCSF and 3 patients received platelet transfusions. Only 1 patient experience febrile neutropenia. The authors concluded "In this study we established the feasibility, tolerability and efficacy of sequential treatement with 6 cycles of FM chemotherapy followed by 90Y ibritumomab tiuxetan as front line therapy for patients with untreated, indolent, nonfollicular NHL. To our knowledge the data repr
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
2. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
3. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
4. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
5. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
6. SGX Initiates Phase I Trials for SGX523
7. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
8. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
9. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
10. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
11. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... LAWRENCE, Mass. , Dec. 22, 2014 /PRNewswire/ ... a leading manufacturer of innovative dialysis products, announced ... (FDA) has cleared its System One™ to perform ... sleeping, known as home nocturnal hemodialysis. NxStage,s® System ... cleared by the FDA for this indication. ...
(Date:12/22/2014)... 2014 Research and Markets ( ... "Investment Analysis of the US Medical Device ... http://photos.prnewswire.com/prnh/20130307/600769 ... device sector identifies the key trends and rationale ... and mergers and acquisitions. The study ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals ... company focused on discovering, developing and commercializing innovative ... technologies, today issued the following open letter to ... , Dr. Med. Sc. Dear RXi ... a number of inaccurate statements posted on certain ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... Decision Resources, one of the world,s leading research ... that, through 2019, an expanding aging population and increases ... percent annual growth in the chronic obstructive pulmonary disease ... findings from the topic entitled Chronic Obstructive Pulmonary ...
... -- DALLAS, Texas, August 31, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
Cached Medicine Technology:An Expanding Aging Population and Increases in Diagnosis and Drug Treatment Will Fuel Steady 4.6 Percent Annual Growth in the Chronic Obstructive Pulmonary Drug Market 2The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 2The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 3The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 4The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 5The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 6The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 7The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 8The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 9
(Date:12/25/2014)... (PRWEB) December 25, 2014 The short film ... was created in honor of a true 9/11 hero, Welles ... film festivals including the 24 hours of Nuremberg International Short ... Bangladesh. , Actress, screenwriter and director Luciana Lagana ... this film together with her husband, Gregory Graham ...
(Date:12/25/2014)... Hills, California (PRWEB) December 25, 2014 ... her home in Woodland Hills, California after an 8 ... passed away on Christmas Eve evening in her home ... with aggressive metastatic breast cancer. , ... for over forty years, she pioneered and championed many ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... sick children with complex chronic illnesses can receive effective, less ... home," with easy access to a team of dedicated health ... likely to become seriously ill and need either hospitalization or ... at an enhanced medical home clinic at the University of ...
(Date:12/25/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- Among early ... treatment, less than half of one percent will eventually ... new analysis reveals. The finding comes from a ... between 1998 and 2007, and it suggests that the ... double what experts had previously thought. "The frequency ...
(Date:12/25/2014)... New York, New York (PRWEB) December 25, 2014 ... ) continue to move forward in a number ... Southern District of West Virginia, Bernstein Liebhard LLP reports. ... the Court is scheduled to convene a Joint Status ... 2015, at 10:00 a.m. Parties have been directed to ...
Breaking Medicine News(10 mins):Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4
... Bluhm Cardiovascular Institute is the first center in ... implant a new experimental left ventricular assist device (LVAD) ... the heart cannot pump enough blood to the body,s ... features the HVAD Pump, the smallest LVAD to ...
... 2009) In recognition of their distinguished contributions to ... Medical Center (LA BioMed) will honor four of its ... May 12 at Trump National Golf Club. , John ... Shapiro, MD, and Mark A. Sperling, MD, will be ...
... for signs of sickness , , MONDAY, April 27 (HealthDay News) ... by the swine flu outbreak is a cause for concern ... began monitoring its borders to contain the outbreak that has ... and Human Services has declared a public health emergency as ...
... should be individualized, men should get baseline reading at ... American Urological Association (AUA) today issued new clinical guidance ... major groups - about prostate cancer screening, asserting that ... to well-informed, men aged 40 years or older who ...
... Patients with stone disease could benefit from drinking ... California, San Francisco suggests that the citrate and ... to inhibit the development of calcium stones. The study ... the American Urological Association (AUA). Increased alkalinity is proven ...
... April 27 Tadalafil may improve lower urinary tract ... from Nashville, Dallas, San Antonio and Indianapolis will present ... the American Urological Association (AUA). In this study, researchers ... or older than 40 years and at least a ...
Cached Medicine News:Health News:Smallest full support heart assist device on trial at Northwestern Memorial 2Health News:Four legendary LA BioMed physician-researchers honored 2Health News:Four legendary LA BioMed physician-researchers honored 3Health News:Four legendary LA BioMed physician-researchers honored 4Health News:Four legendary LA BioMed physician-researchers honored 5Health News:Obama Says Swine Flu Outbreak No Cause for 'Alarm' 2Health News:Obama Says Swine Flu Outbreak No Cause for 'Alarm' 3Health News:Obama Says Swine Flu Outbreak No Cause for 'Alarm' 4Health News:Obama Says Swine Flu Outbreak No Cause for 'Alarm' 5Health News:AUA Counters Mainstream Recommendations with New Best Practice Statement on Prostate-Specific Antigen Testing 2Health News:AUA Counters Mainstream Recommendations with New Best Practice Statement on Prostate-Specific Antigen Testing 3Health News:AUA Counters Mainstream Recommendations with New Best Practice Statement on Prostate-Specific Antigen Testing 4Health News:Drinking Diet Soda May Reduce the Risk of Forming Kidney Stones 2Health News:Tadalafil May Effectively Treat Symptoms of BPH-LUTS in Addition to Erectile Dysfunction 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: